Baricitinib found to be efficacious for hair regrowth in teens with severe alopecia areata
For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study ...
Applied Clinical Trials Online6d
Phase III Trial Finds Baricitinib Boosts Hair Regrowth in Adolescents With Severe Alopecia Areata
The BRAVE-AA-PEDS trial found that once-daily baricitinib significantly improved hair regrowth on the scalp, eyebrows, and ...
Medscape2d
JAK Inhibitor Baricitinib Significantly Restores Hair Growth in Adolescents With Alopecia Areata
Adolescents with alopecia areata achieve hair regrowth with 80% or more of scalp coverage while taking the Janus kinase inhibitor baricitinib, a phase 3 study finds.
Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to ...
Healio11d
Baricitinib effective in adolescents with severe alopecia areata, phase 3 data show
Thirty-six weeks of once-daily, oral baricitinib was associated with greater hair regrowth on the scalp, eyebrows and ...
The American Journal of Managed Care11d
Baricitinib Shows Promise for Pediatric Alopecia in BRAVE-AA-PEDS Study
Brittany Craiglow, MD, FAAD, analyzed the promising use of baricitinib for severe pediatric alopecia areata. She highlighted late-breaking data from the BRAVE-AA-PEDS study (NCT05723198), emphasizing ...
Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss
Eli Lilly And Co (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) said adolescent patients with severe alopecia areata (AA) ...
The American Journal of Managed Care6d
Pediatric Alopecia Areata Treatment With Baricitinib, Combination Therapies, Patient Adherence
In an interview with Brittany Craiglow, MD, FAAD, dermatologist at Dermatology Physicians of Connecticut in Fairfield, she advocates for combination therapies using baricitinib to treat pediatric ...
Incyte, Eli Lilly present results from Phase 3 BRAVE-AA-PEDS study
Late-breaking results from Eli Lilly and Company (LLY) and Incyte (INCY) found adolescent patients with severe alopecia areata, AA, treated ...
MPR1d
Baricitinib Efficacious for Hair Regrowth in Teens With Severe Alopecia Areata
Significantly more patients receiving baricitinib 2 mg, 4 mg had SALT score ≤20, ≤10 versus placebo at week 36 ...
The Victoria Advocate12d
Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
"These initial results are exciting because they demonstrate that baricitinib can provide significant hair regrowth for adolescents at 36 weeks, a promising early signal of baricitinib's potential ...